Trilaciclib: Experimental Treatment for Triple-Negative Breast Cancer (TNBC)
Scientific rationale and therapeutic potential
Trilaciclib is a short-acting CDK4/6 inhibitor given as an intravenous infusion prior to chemotherapy. Trilaciclib is designed to:
- preserve hematopoietic stem and progenitor cell (HSPC) function, as well as immune system function during chemotherapy (myelopreservation);
- enable planned chemotherapy regimens and prime anti-tumor immunity;
- improve patient outcomes by reducing infections, hospitalizations, transfusions and growth-factor usage.
Preclinical and clinical results (see: Publications)
Trilaciclib has potential in triple-negative breast cancer (TNBC) based on:
- preclinical data presented at the American Association for Cancer Research 2015 Annual Meeting and the EORTC-NCI-AACR 2016 Molecular Targets and Cancer Therapeutics Symposium, and published in Molecular Cancer Therapeutics;
- Phase 1 data in healthy volunteers presented at the American Society of Clinical Oncology 2015 Annual Meeting and published in Science Translational Medicine;
- Phase 2 data presented at the 2018 San Antonio Breast Cancer Symposium.
G1's ongoing Phase 2 trial in TNBC